Company intelligence / Profile preview
EpicentRx
La Jolla, California, United Statesepicentrx.com ↗
- Ownership
- Private
- Employees
- ~18
- Development stage
- Phase 3
01
Overview
EpicentRx has demonstrated positive clinical results with its lead programs. RRx‑001 has shown improved overall survival and progression-free survival in glioblastoma patients and positive results as a third-line treatment in SCLC. The company’s therapies are designed to be minimally toxic with no dose-limiting toxicities observed to date. AdAPT‑001 is well tolerated in early trials.[3]
- Therapeutic areas
- OtherGastroenterologyOncologyNeurology
- Modalities
- Small molecules (e.g., RRx-001)Oncolytic viruses (e.g., AdAPT platform)[1][3][4]
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
SciClone Pharmaceuticals International Ltd. – licensing agreement for development/commercialization of RRx‑001 in Greater China.[6]
Beyond the preview
Go deeper on EpicentRx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpicentRx.